X

Trial Profile

Efficacy study of sequential therapy with anthracycline, taxane, and eribulin in patients with HER2-negative locally advanced breast cancer (JBCRG-17)

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 10 Nov 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Anthracyclines (Primary) ; Eribulin (Primary) ; Taxanes (Primary)
Indications Advanced breast cancer; HER2 negative breast cancer
Focus Therapeutic Use

Most Recent Events

23 Sep 2021 Results assessing the clinical response rate and safety of patients with advanced, local, HER2-negative breast cancer to sequential therapy with anthracycline, taxane, and eribulin, published in the Breast Cancer Research and Treatment.
08 Jul 2021 Planned End Date changed from 31 May 2025 to 27 May 2019.
08 Jul 2021 Status changed from active, no longer recruiting to discontinued.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com